LIVZON PHARMA (01513) announced that during its first extraordinary general meeting held on December 10, 2025, the company approved the proposal to appoint Ms. Wang Zhiyao as an independent non-executive director for the 11th board. Her term will commence upon approval at the meeting and continue until the end of the 11th board's tenure.

On the same day, the company convened its first staff representative assembly in 2025. Following a qualification review by the board’s nomination committee, Ms. Ran Yongmei was democratically elected as an employee representative director for the 11th board.

Additionally, the 30th meeting of the 11th board of directors was held, approving adjustments to certain board committee members. The revised composition of the 11th board committees is as follows: - **Audit Committee**: Mr. Bai Hua (Chair), Mr. Luo Huiyuan, Ms. Cui Lijie - **Compensation & Evaluation Committee**: Ms. Cui Lijie (Chair), Mr. Bai Hua, Mr. Tang Yanggang - **Nomination Committee**: Mr. Luo Huiyuan (Chair), Ms. Cui Lijie, Mr. Tao Desheng - **ESG Committee**: Mr. Zhu Baoguo (Chair), Mr. Tang Yanggang, Mr. Bai Hua, Ms. Cui Lijie, Ms. Wang Zhiyao - **Strategy Committee**: Mr. Zhu Baoguo (Chair), Mr. Tang Yanggang, Mr. Tao Desheng.